<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00662012</url>
  </required_header>
  <id_info>
    <org_study_id>A-10950</org_study_id>
    <secondary_id>WU#01-19002</secondary_id>
    <nct_id>NCT00662012</nct_id>
  </id_info>
  <brief_title>Sodium Stibogluconate Treatment of Leishmaniasis</brief_title>
  <official_title>Sodium Stibogluconate Treatment of Leishmaniasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leishmanias is a disease caused by the bite of sandflies and is found in many parts of the
      world including the Europe, Southwest Asia, Africa and the Middle East. This disease is a
      threat for military soldiers in areas where this disease is found. Sodium stibogluconate
      (SSG) or Pentostam (Glaxo Smith Kline, United Kingdom) is an Investigational New Drug (IND)
      product used by the Department of Defense for over 20 years to treat cutaneous, mucosal and
      viseral leishmanias. This drug is not licensed for commercial use in the United States
      because of very limited need for the product in the U.S.A. The objective of this protocol is
      to provide sodium stibogluconate for the treatment of cutaneous leishmaniasis and mucosal
      leishmaniasis (pentavalent antimonials curently considered the drug of choice for these
      infections) Provide sodium stibogluconate as a second line treatment for viscerotropic and
      visceral leishmaniasis (liposomal amphotericin is the drug of choice for these types as it is
      FDA approved for vusceral leishmaniasis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leishmaniasis is a protozoal disease transmitted by sandflies and is endemic in many parts of
      the world including Central and South America, Europe, Southwest Asia, Africa, and the Middle
      East. Infected humans may develop cutaneous (Old or New World), mucocutaneous (New World), or
      visceral leishmaniasis. The disease is a medical threat for military soldiers assigned in
      endemic areas and currently a major cause of morbidity in soldiers deployed to the Middle
      East and a complication of military exercises in Panama, Honduras, and South America.

      Pentavalent antimonials (Pentostam, GSK, UK, and Glucantime, Rhone-Poulenc, France) have been
      used to treat leishmaniasis for more that 50 years. Neither of these drugs are licensed for
      commercial use in the United States, likely because of limited use. Worldwide, there is a
      great deal of experience and use of these products.

      Pentostam or sodium stibogluconate is a pentavalent antimony drug complexed to carbohydrate
      the exact structure and mechanism of action of which are not known. It is provided as a 100
      mg antimony/ml solution that contains a preservative, m-chlorocresol. Most of the dose is
      excreted by the kidneys within 24 hours.

      Pentostam is presently an investigational new drug (IND) product that has been in use by the
      Department of Defense (DoD) for over 20 years for the treatment of cutaneous, mucosal and
      visceral leishmaniasis. In August, 1997, the FDA approved Ambisome (liposomal amphotericin)
      for the treatment of visceral leishmaniasis. As a result, in the treatment of visceral and
      viscerotropic leishmaniasis, the use of antimonials will now be considered a second-line
      therapy

      In 1984, the World Health Organization recommended that the daily dose of antimony in the
      treatment of visceral leishmaniasis be increased to 20 mg/kg/day. A randomized controlled
      trial of 40 subjects with American, New World, cutaneous leishmaniasis (ACL) found 100% cure
      rates with 20 mg/kg/day Sb for 20 days but only a 76% cure if 10 mg/kg/day for 10 days was
      used. A comparison of three treatment schedules in 36 subjects with CL (single rapid
      infusion, continuous 24 hour infusion, or every eight hour doses) found no advantage over
      using once daily dosing. A review of the controlled trials of SSG concludes that a
      recommended course of therapy is 20 mg/kg/day with no upper limit to dose for 20 days for CL
      and 20 mg/kg/day for 28 days for visceral or mucocutaneous leishmaniasis. The Pentostam®
      package insert suggests that 10-20 mg/kg/day with a maximum dose of 850 mg for a minimum of
      20 days be used; however, based on the Centers for Disease Control and Prevention (CDC) and
      Walter Reed Army Medical Center (WRAMC) experience and their practice guidelines, 20
      mg/kg/day with no upper limit to dosage is used. WRAMC recently published their CL treatment
      experience primarily in New World leishmaniasis comparing SSG 20 mg/kg for 10 or 20 days and
      found 100% of volunteers in the 10-day group were cured. In this study 15% were Leishmania
      major infections. Comparable results are expected for Old World leishmaniasis based on
      clinical experience and current literature.

      Detailed toxicity data for the 20 mg/kg/day dose are provided by several studies. Percentages
      from the WRAMC experience are included here. Subjective musculoskeletal complaints are common
      (58%), as well as elevated hepatocellular (67%) and pancreatic enzyme levels (97%) and
      nonspecific electrocardiogram (EKG) changes (T wave changes). These side effects are usually
      reversible, and no deaths have been associated with SSG at WRAMC. Other SSG toxic effects
      include headache (22%), rash (9%), thrombocytopenia, depression of various hematologic cell
      lines (44%), phlebitis, anaphylaxis, inflammation around lesions, and transient coughing
      after infusion. Other associated symptoms include anorexia, malaise, myalgia, abdominal pain,
      headache, lethargy, sweating, vertigo, facial flushing, initial worsening of skin lesions,
      epistaxis, jaundice and peripheral neuropathy. In our above-mentioned 10 versus 20 days
      study, the adverse events (AE) were significantly decreased in the cohort receiving the 10
      days versus 20 with myalgias in 42% (versus 68%), with less chemical pancreatitis and fewer
      hematologic parameter disorders. Angioedema during SSG infusion has recently been described
      in two subjects at WRAMC. Both subjects responded quickly to benadryl treatment without
      complications. Both subjects were subsequently skin tested with SSG intradermally for
      hypersensitivity and one reacted.

      Alternative heat therapies have been used to successfully treat CL. Laboratory investigation
      showed that Leishmania infection is sensitive to heat. Various forms of heat application in
      human CL has shown variable efficacy. The TTI Thermomed™ device has been cleared as a 510-k
      device by the U.S. Food and Drug Administration (FDA) for use in the treatment of CL. This
      device uses localized current field radio frequency. Other therapies that may be effective
      for treating CL include topical paromomycin and oral fluconazole.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Safety Endpoint - Frequency of Complications of Therapy</measure>
    <time_frame>5 years</time_frame>
    <description>The primary safety endpoint is the frequency of complications of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Lesions, Resolution of Fever and Lab Abnormalities for Visceral Leishmaniasis and Regression of Mucosal Lesions .</measure>
    <time_frame>5 years</time_frame>
    <description>Improvement of lesions for cutaneous leishmanias, resolution of fever and lab abnormalities for visceral leishmaniasis and regression of mucosal lesions for mucocutaneous disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">414</enrollment>
  <condition>Leishmaniasis</condition>
  <arm_group>
    <arm_group_label>Sodium Stibogluconate (SSG) 20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Stibogluconate (SSG)</intervention_name>
    <description>100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.</description>
    <arm_group_label>Sodium Stibogluconate (SSG) 20 mg/kg</arm_group_label>
    <other_name>Pentostam (GlaxoSmithKline)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DoD healthcare beneficiary of any age and gender.

          -  Clinicoepidemiologic or parasitologic diagnosis (microscopy, PCR or culture) of
             Leishmania infection.

          -  Able to provide informed consent or assent (children).

          -  All participants (both male and female) must agree to take precautions not to become
             pregnant or father a child for at least 2 months after receiving SSG.

        Exclusion Criteria:

          -  Pregnancy. Females of childbearing potential must have negative urine human chorionic
             gonadotropin hormone (HCG) within 96 hours start of infusion period.

          -  History of hypersensitivity to pentavalent antimonials.

          -  Any of the following on screening examination:

               1. QTc interval greater or equal to 0.5 sec

               2. Severe cardiac disease (disabling valvular heart disease, myopathy, or
                  arrhythmias)

               3. History of recurrent pancreatitis

               4. Liver failure or active hepatitis with transaminases &gt; 3x upper limit of normal

               5. Renal failure or creatinine &gt; 2.5 mg/dL

               6. Thrombocytopenia (platelets &lt;100,000/mm3)

               7. White blood cell count &lt; 2000 / mm3

               8. Hematocrit &lt; 30 %
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Wortmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Medical Center, Infectious Disease</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2008</study_first_posted>
  <results_first_submitted>September 28, 2016</results_first_submitted>
  <results_first_submitted_qc>January 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>January 18, 2017</last_update_submitted>
  <last_update_submitted_qc>January 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leishmaniasis</keyword>
  <keyword>Sodium stibogluconate</keyword>
  <keyword>Pentostam</keyword>
  <keyword>sand fly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leishmaniasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antimony Sodium Gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Walter Reed Army Medical Center</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment commenced on 11May2002 with follow-up periods ranging from 12 to 24 months after completion of treatment. Treatment was received at Walter Reed Army Medical Center, Washington, DC, USA.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SSG 20 mg/kg</title>
          <description>All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
Sodium Stibogluconate (SSG): 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="414"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="327"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat, evaluable, and safety populations included all patients who received at least 1 dose of SSG. Data were displayed by regimen and overall for patients with CL.</population>
      <group_list>
        <group group_id="B1">
          <title>SSG 20 mg/kg</title>
          <description>All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
Sodium Stibogluconate (SSG): 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="414"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="7.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All subjects must be willing to locate to the WRAMC area during treatment</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion data - Duration since onset</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111.6" spread="47.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion data - Number of lesions</title>
          <description>Number of lesions on body</description>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Safety Endpoint - Frequency of Complications of Therapy</title>
        <description>The primary safety endpoint is the frequency of complications of therapy</description>
        <time_frame>5 years</time_frame>
        <population>Analysis was per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>SSG 20 mg/kg</title>
            <description>All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
Sodium Stibogluconate (SSG): 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Safety Endpoint - Frequency of Complications of Therapy</title>
          <description>The primary safety endpoint is the frequency of complications of therapy</description>
          <population>Analysis was per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Lesions, Resolution of Fever and Lab Abnormalities for Visceral Leishmaniasis and Regression of Mucosal Lesions .</title>
        <description>Improvement of lesions for cutaneous leishmanias, resolution of fever and lab abnormalities for visceral leishmaniasis and regression of mucosal lesions for mucocutaneous disease.</description>
        <time_frame>5 years</time_frame>
        <population>Analysis per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>SSG 20 mg/kg</title>
            <description>All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
Sodium Stibogluconate (SSG): 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Lesions, Resolution of Fever and Lab Abnormalities for Visceral Leishmaniasis and Regression of Mucosal Lesions .</title>
          <description>Improvement of lesions for cutaneous leishmanias, resolution of fever and lab abnormalities for visceral leishmaniasis and regression of mucosal lesions for mucocutaneous disease.</description>
          <population>Analysis per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The study included a screening/baseline period, a 10-20 or 28-day treatment period, and a 12-24 month follow-up period.</time_frame>
      <desc>10 days for cutaneous leishmaniasis due to L. major, 20 days for cutaneous leishmaniasis due to other species and for some more severe or less responsive L. major infections, 28 days for mucocutaneious, viscerotripic, or visceral leishmaniasis.</desc>
      <group_list>
        <group group_id="E1">
          <title>SSG 20 mg/kg</title>
          <description>All consented subjects who meet all inclusion and no exclusion criteria will enter this open label protocol and be treated with 20 mg/kg once daily intravenously with SSG.
Sodium Stibogluconate (SSG): 100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Gall Bladder Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Meningitis Aseptic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Cutaneous Leishmaniasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Heat Exhaustion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Limb Traumatic Amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Road Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy Liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Post-Traumatic Stress Disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioneurotic Oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Swelling Face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphacele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Aneurysm Ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="414" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="59" subjects_affected="59" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Bundle Branch Block Right</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle Branch Block Left</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Conduction Disorder</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Dilatation Atrial</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Supraventricular Extrasystoles</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="55" subjects_affected="55" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Ventricular Hypertrophy</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="118" subjects_affected="118" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Abdominal Tenderness</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="59" subjects_affected="59" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Gastroesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="135" subjects_affected="135" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="151" subjects_affected="151" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Stomach Discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Early Satiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="292" subjects_affected="292" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Feeling Hot</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Infusion Related Reaction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Infusion Site Reaction</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="45" subjects_affected="45" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="74" subjects_affected="74" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="245" subjects_affected="245" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Anion Gap Decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increase</sub_title>
                <counts group_id="E1" events="202" subjects_affected="202" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Albumin Decreased</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Amylase Increased</sub_title>
                <counts group_id="E1" events="273" subjects_affected="273" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Billirubin Increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Calcium Increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Chloride Increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Glucose Decreased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Potassium Decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Potassium Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Sodium Increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Blood Urea Increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Body Temperature Increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Electrocardiogram P Wave Abnormal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QRS Complex Abnormal</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST Segment Abnormal</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST Segment Elevation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T Wave Abnormal</sub_title>
                <counts group_id="E1" events="83" subjects_affected="83" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T Wave Inversion</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Electrocardiogram Abnormal</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Electrodardiogram Repolarisation Abnormality</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Eosinophil Count Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Eosinophil Percentage Increased</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Haematocrit Decreased</sub_title>
                <counts group_id="E1" events="79" subjects_affected="79" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Heart Rate Increased</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" events="331" subjects_affected="331" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Lymphocyte Count Decreased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Lymphocyte Percentage Decreased</sub_title>
                <counts group_id="E1" events="65" subjects_affected="65" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Lymphocyte Percentage Increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Monocyte Count Increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Monocyte Percentage Increased</sub_title>
                <counts group_id="E1" events="76" subjects_affected="76" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Increased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Neutrophil Percentage Decreased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Neutrophil Percentage Increased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pancreatic Enzymes Increased</sub_title>
                <description>The low frequency of event relative to the laboratory data, show a high frequency of increases in pancreatic enzymes,is due to the fact that most abnormalities in pancreatic enzymes were coded to the specific pancreatic enzyme (amylase or lipase)</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" events="88" subjects_affected="88" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Protein Total Decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>QRS Axis Abnormal</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Red Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Tuberculin Test Positive</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Urine Antimony Increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" events="120" subjects_affected="120" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorxia</sub_title>
                <counts group_id="E1" events="54" subjects_affected="54" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="286" subjects_affected="286" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Joint Stiffness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="253" subjects_affected="253" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pain in Jaw</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="212" subjects_affected="212" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Post-traumatic Stress Disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Sleep Disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="67" subjects_affected="67" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Rash Papular</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Rash Pruritic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="414"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="414"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Naomi Aronson, MD</name_or_title>
      <organization>Uniformed Services University of Health Sciences (USUHS)</organization>
      <phone>(301) 295-3621</phone>
      <email>naomi.e.aronson.civ@mail.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

